We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New therapies for hepatitis C virus infection.
- Authors
Soriano, Vincent; Peters, Marion G; Zeuzem, Stefan
- Abstract
Chronic hepatitis C virus (HCV) infection remains a global health threat with approximately 175 million carriers worldwide. Currently, treatment consists of pegylated interferon alpha plus ribavirin for 12-72 weeks, depending on HCV genotype, baseline viral load, and initial virological response to therapy. Serious adverse effects and limited sustained virological responses with this therapy warrant the need for novel HCV therapies. Specifically targeted antiviral therapies designed to inhibit the HCV serine protease and the RNA-dependent RNA polymerase have recently entered clinical development. Herein, the main characteristics of these new antiviral agents and the most important challenges arising with their use--namely, toxicities and rapid selection of resistance--are discussed.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Vol 48, Issue 3, p313
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/595848